Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XEN1101 TMS study in healthy males
NCT03468725Phase 1Completed
- Sponsor
- Xenon Pharmaceuticals
- Start
- Feb 2018
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in focal onset seizure and epilepsy comparing XEN1101 Sequence with Placebo Sequence (2 arms). Primary endpoints: Number of participants with adverse events, Resting 12-lead electrocardiogram and 2 more. Started Feb 2018; status: completed.
02
Drugs
azetukalner
03
Conditions
focal onset seizureepilepsy
Beyond the preview
Go deeper on NCT03468725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03468725.